Completed
PHASE3
INTERVENTIONAL
NCT03305016
A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
A 26 week trial of TransCon hGH, a long-acting growth hormone product, administered once-a-week. Approximately 150 children (males and females) with growth hormone deficiency (GHD) will be included. All study participants will receive TransCon hGH. This is a global trial that will be conducted in, but not limited to, the United States, Canada, Australia, and New Zealand.
Interventions
Name:
TransCon hGH
Type:
DRUG
Description:
Once weekly subcutaneous injection at a starting dose of 0.24 mg/kg/week
Primary Outcomes
Measure:
Number of Participants With Treatment-Emergent Adverse Events [Safety and Tolerability]
TimeFrame:
26 weeks
Description:
Safety and tolerability of weekly lonapegsomatropin (TransCon hGH) treatment
Trial Information
NCT ID
NCT03305016
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE3
Sponsor
Ascendis Pharma Endocrinology Division A/S
Last Updated
December 15, 2025